For metastasis, cell populations have to migrate to distant locations. For this, cells

have to acquire more alterations that click here enable the complex processes underlying metastasis. These processes involve tissue invasion, entering, and evasion of blood or lymphatic vessels to reach distant location but also survival and proliferation at distinct locations. Hence, melanocytic cells have to become largely independent from their normal microenvironment [7]. 2.2. Inhibitors,research,lifescience,medical Melanoma Progression: Risk Factors and Biological Drivers The most important risk factor for melanoma is UV irradiation upon sun exposure. Whole genome sequencing revealed that melanoma is the tumor type with the most DNA mutations—many being typical for UV-induced mutations [8]. Despite the plethora of DNA alterations, two gene mutations were found to be rather common in melanoma. A general overview on these mutations and their key players are schematically represented in Figure 1. Figure 1 Schematic Inhibitors,research,lifescience,medical summary of the most common mutations found in melanoma patients. The most common risk for melanoma is UV, and most DNA alterations are typically UV-induced. Family history of melanoma Inhibitors,research,lifescience,medical accounts for a two-fold risk increase, through mutations … With respect to mutation frequency, the mitogen-activated protein kinase (MAPK) pathway plays a central role in melanoma. Activation of growth factor receptors leads to activation of RAS molecules which activate in a downstream

phosphorylation cascade RAF, MEK, and ERK kinases. ERK kinase phosphorylates a panel of substrates leading to increased cell proliferation and survival. RAS molecules, Inhibitors,research,lifescience,medical comprising HRAS, KRAS, and NRAS, are small GTPases

or G proteins, and activating mutations in NRAS are found in 10%–20% of melanomas. RAS molecules activate RAF family members consisting of ARAF, BRAF, and CRAF. A single nucleotide mutation in BRAF at amino acid 600—whereupon a valine (V) aminoacid is replaced by glutamic acid (E)—represents the most common mutation in BRAF. This mutant V600EBRAF leads to an alternative protein structure and to a constitutive active protein. 50%–60% of melanomas contain an activating mutation Inhibitors,research,lifescience,medical in BRAF [9]. The outstanding importance of the RAS/RAF signaling pathway is documented by the observation others that BRAF and NRAS mutations—exclusively NRAS or BRAF is mutated in a tumor—together are found in over 80% of melanomas and by inhibitors of mutated BRAF that are clearly effective in melanoma therapy. Interestingly, V600EBRAF has also been reported in melanocytic nevi [10–12], which rarely develop into melanoma. Nevi are described to be senescent, and, similarly, expression of V600EBRAF in melanocytes induces oncogene-induced senescence [6]. These findings imply that BRAF mutations are involved in the first transition state of melanoma progression. Hence, this mutation per se is insufficient to drive tumorigenesis, rather additional alterations are required to avoid dormancy.